Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (277)	6/11/1998 10:57:00 AM
From: Anthony Wong	Read Replies (2) \| Respond to of 1722

Malaysia to market impotence drug Viagra Thursday June 11, 9:24 am Eastern Time KUALA LUMPUR, June 11 (Reuters) - Blockbuster impotence drug Viagra will soon be available in Malaysia, the national Bernama news agency said on Thursday. The pill, made by U.S. based Pfizer Inc (PFE - news), could only be sold on doctors' prescription as its side-effects were unknown, Bernama quoted M. Mahalingam, the parliamentary secretary to Malaysia's health ministry, as saying. The government had also not decided on whether to control the price of the pill, Mahalingam said. Pills claiming to cure impotency are widely peddled by road-side medicine men in Malaysia but their effectiveness is unknown. biz.yahoo.com

To: Anthony Wong who wrote (277)	6/11/1998 11:07:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

DuPont Merck Files FDA Application for HIV Drug Sustiva June 11, 1998 10:18 AM FDA Designates As Fast-Track Drug By Otesa Middleton WASHINGTON (Dow Jones)--DuPont Merck Pharmaceutical Co. submitted to the Food and Drug Administration Thursday a new drug application Thursday for the company's once-a-day HIV drug Sustiva. The FDA, which designated Sustiva a fast-track drug, plans to make a decision on the product within six months. DuPont & Co. (DD) announced last month that it will buy Merck & Co.'s (MRK) 50% interest in their DuPont Merck venture. The deal, expected to close July 1 will make Sustiva, if approved, the first HIV drug of the new DuPont Pharmaceuticals Co.